| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
According to Benzinga Pro data, during Q2, Epizyme (NASDAQ:EPZM) posted sales of $27.53 million. Earnings were up 35.6%, but Ep...
Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors ne...
Epizyme (NASDAQ:EPZM) reported quarterly losses of $(0.21) per share. This is a 66.67 percent increase over losses of $(0.63) p...
Upgrades
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5571&...
Cowen & Co. analyst Joseph Thome downgrades Epizyme (NASDAQ:EPZM) from Outperform to Market Perform and announces $1.5 p...
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court over...
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
Here's a roundup of top developments in the biotech space over the last 24 hours:
